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Context: Individual patients vary in their response to growth hormone (GH). No large-scale 
genome-wide studies have looked for genetic predictors of GH responsiveness.
Objective: To identify genetic variants associated with GH responsiveness.
Design: Genome-wide association study (GWAS).
Setting: Cohorts from multiple academic centers and a clinical trial.
Patients: A total of 614 individuals from 5 short stature cohorts receiving GH: 297 with 
idiopathic short stature, 276 with isolated GH deficiency, and 65 born small for gestational age.
Intervention: Association of more than 2 million variants was tested.
Main Outcome Measures: Primary analysis: individual single nucleotide polymorphism (SNP) 
association with first-year change in height standard deviation scores. Secondary analyses: SNP 
associations in clinical subgroups adjusted for clinical variables; association of polygenic score 
calculated from 697 genome-wide significant height SNPs with GH responsiveness.
Results: No common variant associations reached genome-wide significance in the primary 
analysis. The strongest suggestive signals were found near the B4GALT4 and TBCE genes. After 
meta-analysis including replication data, signals at several loci reached or retained genome-
wide significance in secondary analyses, including variants near ST3GAL6. There was no 
significant association with variants previously reported to be associated with GH response nor 
with a polygenic predicted height score.
Abbreviations: beta4GalT, beta-1,4-galactosyltransferase; GH, growth hormone; 
GHD, GH deficiency; GWAS, genome-wide association study; HE, HumanExome; HO, 
Illumina HumanOmni1-Quad BeadChip; HOEE, HumanOmniExpressExome; IGF, insulin-
like growth factor; ISS, idiopathic short stature; MAF, minor allele frequency; MPH, 
midparental height; rhGH, recombinant GH; SDS, standard deviation score; SGA, small 
for gestational age; SNP, single nucleotide polymorphism.
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Conclusions: We performed the largest GWAS of GH responsiveness to date. We identified 2 
loci with a suggestive effect on GH responsiveness in our primary analysis and several genome-
wide significant associations in secondary analyses that require further replication. Our results 
are consistent with a polygenic component to GH responsiveness, likely distinct from the genetic 
regulators of adult height. (J Clin Endocrinol Metab 105: 3203–3214, 2020)
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G rowth disorders resulting in short stature have numerous etiologies, including many different 
inherited clinical syndromes. Specific genetic etiolo-
gies include disorders of the growth hormone–insulin-
like growth factor-1 (GH/IGF-1) axis—GH deficiency 
(GHD) and hormone resistance—and a wide variety of 
additional genetic syndromes such as Turner syndrome, 
Noonan syndrome, and skeletal dysplasias (1-3). Other 
children with short stature are born small for gesta-
tional age (SGA) and do not have “catch-up” growth. 
Finally, the majority of children with short stature have 
no known specific cause and are classified as idiopathic 
short stature (ISS).
Recombinant human GH has been used in pediatric 
populations to increase height for individuals with many 
of these conditions. There is substantial variability in 
growth response to GH, not only across types of growth 
disorders but also between individuals who share the 
same general etiology for their short stature (4-6). The 
variable response seen between different disorders sug-
gests that the sensitivity to treatment is associated with 
the underlying cause of each condition. However, the 
additional variability within each disorder indicates that 
individual factors, including possibly genetic variation, 
also contribute to GH responsiveness.
Previously, disease-specific models have been de-
veloped to predict a patient’s response to GH. These 
models include multiple clinical variables such as par-
ental heights, age at GH initiation, degree of short 
stature, peak GH levels on stimulation testing, GH 
dose, and birth parameters (7). However, these clinical 
parameters only partially predict variation in treat-
ment response. Given the inclusion of parental height 
(a proxy for genetic determinants of height) in predic-
tion models, and the high heritability of height, it is 
quite plausible that genetic variation could influence 
response to GH. Furthermore, identifying genetic vari-
ants that influence response could shed light on the 
biological mechanisms underlying the variability in re-
sponse to GH therapy.
Several studies have proposed candidate variants in 
single genes within the GH/IGF-1 axis for influencing 
GH response. The most widely studied of these is a 
polymorphism in GHR that deletes exon 3 (GHR-
d3), which has been associated with response to GH 
therapy in children with short stature. However, this 
association has only been seen in small samples and 
has not been consistently replicated (8-12). Similarly, a 
polymorphism in the IGFBP-3 promoter has been asso-
ciated with GH response, but this has not been robustly 
replicated (13, 14). The PREDICT study was designed 
to take a more comprehensive approach to examining 
genetic predictors of GH response (15). In that study, 
a more extensive candidate gene study was performed: 
170 patients (110 with GHD and 60 with Turner 
syndrome) underwent genotyping of approximately 
1500 single nucleotide polymorphisms (SNPs) in a list 
of 103 candidate genes related to growth. Additionally, 
baseline gene expression analysis was performed in a 
subset of patients. The genotypes and gene expression 
profiles were then correlated with first-year GH re-
sponse. The study identified a total of 11 genes associ-
ated with GH responsiveness in patients with GHD and 
10 genes in patients with Turner syndrome. However, 
a subsequent replication study was performed by the 
same research group in which none of the original SNP 
signals were reliably replicated (16). There was some 
suggestive evidence for signals in the SOS1 and INPPL1 
genes. Ultimately, they concluded that genotype infor-
mation did not add much to the predictive capability of 
clinical parameters in determining GH responsiveness. 
The PREDICT study did identify gene expression pro-
files associated with both growth response (15) as well 
as with increase in IGF-1 levels at 1 month of treatment 
(17). Using bioinformatics techniques, they were able 
to identify pathways, such as glucocorticoid response, 
which are potentially involved in GH responsiveness.
To date, there have be no large genome-wide asso-
ciation studies (GWASs) of GH responsiveness, which 
would provide a comprehensive assessment of the role 
of common genetic variation in GH response. Recent 
GWASs of adult height have identified hundreds of as-
sociated common variants (18) and, as suggested by 
the correlation between parental height and GH re-
sponse, these may also be candidates for influencing 
GH response and as such merit additional atten-
tion. Finally, rarer genetic variants influence height, 
including those responsible for single-gene disorders 
(19, 20), and these may also influence GH response. 
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stature homeobox-containing gene deficiency (19)) are 
characterized by better responses to GH than others 
(such as spondyloepiphyseal dysplasia (20)), consistent 
with the idea that genetic factors may influence GH 
response.
To search for genetic variation that affects response 
to GH, we carried out what is to our knowledge the lar-
gest GWAS of response to GH, consisting of a total of 
614 children including 276 with idiopathic GHD, 297 
children with ISS, and 41 children born SGA (with nei-
ther GHD nor ISS). We identify several suggestive can-
didate polymorphisms for influencing GH response and 
also examine the role of height-associated variants on 
GH response. Finally, we observe no evidence to sup-
port the previously reported association between the 




The study included 614 children who were treated 
with GH on the basis of the diagnosis of GHD, SGA, or 
ISS. Individuals were recruited from 5 cohorts including 
the Boston Children’s Hospital short stature cohort, 
Barcelona, Sweden, a Pfizer USA clinical trial for pa-
tients with ISS, and individuals who were previously 
collected by KIGS investigators (Pfizer International 
Growth Database). The majority (504) of these samples 
are of self-described European ancestry. A  replication 
sample from Brazil consisted of 113 individuals treated 
with GH for GHD, SGA, or ISS.
The study was approved by the Institutional 
Review Board of Boston Children’s Hospital as well 
as by local review boards in Barcelona, Sweden, 
Pfizer USA, and KIGS (Brazil). Written informed con-
sent was obtained from all patients’ parents or legal 
guardians.
All clinical information was abstracted from the 
available medical records/research databases at the 
respective centers. For all patients, we collected in-
formation on birth weight, gestational age, peak GH 
value during pretreatment testing for GHD, age and 
height at GH start, average GH dose, parents’ heights, 
and height at the end of 1 year of GH therapy. Height 
standard deviation scores (SDSs) were calculated by 
adjusting for age and gender according to Prader et al 
(21). Birth weight SDSs were calculated according to 
Niklasson et  al (22). The midparental height (MPH) 
SDS was calculated by the following: (father’s height 
SD score + mother’s height SD score) ÷ 1.61 (23). 
Height gain (delta height) was defined by the difference 
between height SDS at the end of 1 year of treatment 
and the height SDS at start of GH therapy.
Patients with known chromosomal disorders or 
other significant comorbid conditions were excluded 
from the study. We stratified samples by diagnosis. 
Patients with a peak GH value below 10 ng/mL were 
classified as GHD. Due to the nature of the cohort, 
GH levels were not assayed centrally but rather were 
based on each center’s reported values. Patients were 
excluded if they had additional pituitary hormone de-
ficiencies. Patients who had a birth weight SDS below 
–2 were classified as SGA. Patients could be assigned 
to both the SGA and GHD categories. Patients who 
did not meet either of these criteria were classified 
as ISS. All female patients were required to remain 
prepubertal throughout the study period, which was 
defined as Tanner stage 1 breast development. Male 
participants were required to have testicular volumes 
≤6 cc or be documented as Tanner stage ≤2 at study 
completion. The clinical characteristics of the patients 
are summarized in Table 1.
Genotyping and quality control
Samples were genotyped using either a combination 
of the Illumina HumanOmni1-Quad BeadChip (HO) 
and HumanExome (HE) BeadChip platforms, or on the 
HumanOmniExpressExome (HOEE) BeadChip v1.0 or 
v1.2 platforms; all of these platforms cover a similar 
genome-wide set of common variants and a more com-
prehensive set of exonic variants. We used Illumina’s 
GenCall algorithm to generate genotype calls for all 
platforms. For the rarer exonic variants, we generated 
a second set of genotype calls using zCall (24), which is 
specifically designed for calling rare SNPs from array-
based platforms.
Quality control was performed separately for each 
of the platforms (HO, HE, and HOEE). The minimum 
overall call rate for passing samples was 95%. Samples 
were also removed for being outliers for amount of 
heterozygosity, mismatch between reported gender 
and genotypic data, or close relationship (estimated 
genomic identity by descent ≥0.2) with other sam-
ples. Self-reported ancestry and gender were compared 
with ancestry and sex directly estimated from the gen-
etic data; discordant samples were removed. Standard 
additional filters were applied to remove poorly geno-
typed SNPs, including variant call rate <95%, Hardy-
Weinberg equilibrium P value < 10–6, and evidence of 
nonrandom missingness or batch effects. In total, 588 
individuals had genotype data passing quality control 
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Genotype imputation
To expand the coverage of the genotyping platforms 
to include the vast majority of common variants, we 
imputed genotypes for all polymorphic markers in the 
1000 Genomes Phase I  Integrated Release Version 3 
(March 2012) (25), using the program IMPUTE2 (26, 
27), thereby generating datasets of 36 388 217 auto-
somal and 1 250 157 sex chromosomal variants. The 
data from HO and HE platforms were merged and 
then imputed; the remaining samples genotyped on the 
HOEE platform were imputed separately. We removed 
SNPs with a low quality of imputation (info score <0.4).
Association analysis
The primary outcome was the change in height SDS; 
we performed an inverse normal transformation to en-
sure normality of the outcome variable, but results were 
similar if this transformation was omitted. We carried 
out association testing between this outcome and SNP 
genotype (coded as allele dosage between 0 and 2), using 
an additive model in a regression framework imple-
mented in PLINK (28). We performed analyses stratified 
by diagnosis (all diagnoses, ISS only, and GHD only; 
the number of SGA samples was too small for reliable 
analyses) and by ancestry (all ancestries and European 
ancestry only). For each analysis, we used 2 different 
models: a minimally adjusted model (age and gender in-
cluded as covariates) and a maximally adjusted model 
(age; gender; gestational age; birth weight SDS; age at 
start of GH therapy; GH dosage; height SDS at start of 
GH therapy; MPH; and whether the patient has mild or 
severe GHD, defined as a peak GH level <5, included as 
covariates). In addition, principal components (29) were 
included as covariates to account for ancestry; for the 
multiethnic analysis, 10 principal components were in-
cluded; for European samples, 3 principal components 
were included. The primary analysis was considered to 
be all ancestries, all diagnoses, and a minimally adjusted 
model (Fig. 1).
To account for the potential confounding effect due 
to different genotyping platforms, the analyses were per-
formed separately for the Pfizer USA samples genotyped 
on HO/HE and all other samples genotyped on HOEE, 
and results were meta-analyzed. For meta-analysis, 
we used the inverse-variance fixed effects method to 
combine the results, using METAL (30), weighed by 
standard error. Genome-wide significance for our pri-
mary analysis was set at P < 5 × 10-8.
Association analysis of low-frequency coding 
variants
For rarer (minor allele frequency <5%) coding vari-
ants represented on the exome chip, 2 sets of ana-
lyses were performed using rare variant tests (31). We 
performed association analysis of each variant indi-
vidually (single-variant analysis) and aggregate ana-
lysis of missense, splice, and loss-of-function variants 
within each gene (gene-based analysis). Gene-based 
analyses were performed with sequence kernel asso-
ciation tests (32), and meta-analysis of results from 
the 2 genotyping platforms were performed using 
RAREMETAL (33).
For single-variant exome analysis, we set the signifi-
cance threshold for single-variant association analysis 
as P < 6.93 × 10−7 (Bonferroni correction for 72 171 
polymorphic variants) for analysis of samples with GH 
responsiveness. The significance threshold for a gene-
based test association as P < 2.5 × 10−6 (Bonferroni cor-
rection for 20 000 genes). The analyses were carried out 
under the same phenotypic models as for GWAS.
Association analysis of previously reported height-
associated variants
For each individual, we calculated a genetic poly-
gene score (34) as implemented in PLINK (28), using 
697 height-associated loci identified by the GIANT con-
sortium (18). Specifically, the reported regression coeffi-
cient of each SNP on height and the individual genotype 
at each SNP is used to create a weighted polygene score 











38.6 (2.9) 37.2 (3.1)
Birth weight (g) 2969 (693) 2754 (809)
Birth weight SDS –0.70 (1.14) –0.60 (1.48)
Midparental height 
(cm)
164.6 (5.8) 161.9 (5.35)
Age at start (years) 8.14 (2.71) 8.31 (2.55)
Average growth 
hormone dose  
(mg/kg/week)
0.28 (0.12) 0.29 (0.06)
Height at start (Prader 
SDS)
–3.00 (0.72)  –3.77 (1.18)
Δ height SDS during 
first year of therapy




SGA & GHD 24 3
The numbers in parens are SD, standard deviations. The “SDS” listed 
for Birth Weight SDS, Prader SDS and Height SDS are standard devi-
ation scores.
Abbreviations: GHD: growth hormone deficiency; GWAS, genome-
wide association study; ISS, idiopathic short stature; SDS: standard 
deviations above or below the mean; SGA: small for gestational age; 
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for each individual. We calculated the variance in GH 
response explained by this polygene score (adjusted R2 
estimated from a linear regression model incorporating 
the score as the predictor and the normalized height 
SDS as an outcome, adjusting for age at GH initiation 
and gender).
Association analysis of GHR-d3 and IGFBP3 
variants
We tested for association with variants previously 
reported to be associated with GH response, using the 
methods described above. For the GHR-d3 variant (10), 
we used as a proxy the SNP rs6873545 (r2 between 
GHR-d3 and rs6873545 = 1 in the HapMap CEU 
European ancestry sample); we imputed the previously 
reported IGFBP3 rs2854744 variant.
Validation and replication of variants with 
suggestive associations to GH response
We used PLINK to “clump” variants into loci based 
on linkage disequilibrium (r2 > 0.5), with a single lead 
variant in each locus selected based on the best P value. 
We selected for additional genotyping 3 variants that 
had associations P < 5 × 10-7 in the primary analysis and 
5 additional variants with P < 5 × 10-8 in any secondary 
analysis, as well as an additional 29 variants with as-
sociations P < 5 × 10-7 in any secondary analysis. We 
performed Sanger sequencing in a subset of the GWAS 
samples to confirm good agreement with the original 
GWAS data before proceeding to genotyping. In total, 
we obtained genotype data in the Brazilian replication 
sample for 26 of these 37 SNPs; 5 of the 28 SNPs were 
monomorphic in the replication sample and were not 
analyzed further. Genotyping was performed using the 
Sequenom MassArray platform as previously described 
(35) or, for a subset of variants that could not be geno-
typed successfully, by Sanger sequencing.
Results
To search for genetic determinants of response to GH, 
we studied 614 children treated with GH and assem-
bled from several studies (Table 1; see Methods). The 
participants were categorized as having a diagnosis of 
GHD (N = 276), SGA (N = 41), or ISS (N = 297). The 
majority (N = 504) of these samples were of European 
ancestry. The primary outcome in our study was the in-
crement in height SDS during the first year of therapy. 
We first performed a GWAS and imputed (26, 27) geno-
types for all polymorphic variants with frequency >1% 
in the 1000 Genomes Phase I Integrated Release Version 
3 (March 2012) (25). Our primary analysis included all 
samples, regardless of diagnosis, and was adjusted for 
age, sex, and principal components of genetic ancestry 
(Fig. 1; see Methods). We also performed secondary ana-




Primary analysis: All 
ancestries, minimally 
adjusted model 














Validate and replicate 
suggesve findings 
Figure 1. Analysis plan for testing association to growth hormone response. The primary analysis was to combine patients in all 3 categories: 
growth hormone deficiency (GHD), small for gestational age (SGA) and idiopathic short stature (ISS), including all ancestries and performing a 
minimally adjusted analysis (age, sex, and principal components of genetic ancestry). Secondary analyses included testing GHD or ISS alone, limiting 
the analyses to individuals of European ancestry and adjusting for additional covariates. Additional covariates were gestational age in weeks, 
birthweight standard deviation score (SDS), age at GH start, average GH dose, height SDS (Prader) before treatment, average height of parents, 
and severity of GHD. For principal components of ancestry, the top 10 eigenvalues were used for all ancestry analyses and the top 3 eigenvalues 
for analyses of European ancestry samples. For single-variant analysis, associations were considered to have genome-wide significance if they 
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a more extensive set of covariates (maximally adjusted; 
see Methods). The distributions of test statistics for each 
analysis were not significantly inflated: genomic infla-
tion correction factors (λ GC) ranged between 1.004 and 
1.021, indicating minimal systematic bias (Fig. 2).
GWAS analysis of common variants with GH 
response
We first tested common variants with minor allele 
frequency (MAF) above 1% for association with GH 
response. In our primary analysis (Fig.  1), no vari-
ants achieved genome-wide significance (P < 5 × 10-8; 
Table 2). The strongest suggestive (P < 5 × 10–7) associ-
ations with GH response were observed with a common 
variant near the B4GALT4 gene: rs7628585 (intronic, 
MAF = 0.182; P = 5.54 × 10–8); (Fig.  3) and with a 
common SNP in the TBCE gene, rs1977748 (intronic, 
MAF = 0.411; P = 3.75 × 10–7).
In secondary analyses, 5 SNPs had association P 
values below 5 × 10–8 (Table 2); all of these had minor 
allele frequencies below 5%. In light of the sample size of 
this study, these associations, especially those specific to 
1 diagnosis, should be viewed as tentative in the absence 
of additional replication. A low-frequency intronic SNP 
(rs55704135, MAF = 3%) in the UBE4B gene showed 
the strongest association to GH response in the analysis 
of all European ancestry individuals under the max-
imally adjusted model (P = 4.2 × 10–9). An intergenic 
SNP (rs189532746, frequency = 1.3%) between CPOX 
and ST3GAL6 showed its strongest association in the 
analysis of individuals with ISS of all ancestries under 
the minimally adjusted model (P = 6.95 × 10–9). An 
intergenic SNP (rs78263566, frequency = 2.5%) be-
tween CLEC7A and OLR1 and an intronic SNP 
(rs74523128, frequency = 1.0%) in LAPTM4B showed 
strongest associations in the analyses of individuals with 
GHD under the maximally adjusted model in European 
ancestry individuals (P = 8.5 × 10–9 and P = 1.5 × 10–8). 
Finally, a low-frequency intronic SNP (rs144751704, 
MAF = 1.4%) located in the NT5DC1 gene and up-
stream of COL10A1 showed the strongest association 
to GH response in the analysis of all European an-
cestry individuals under the minimally adjusted model 
(P = 2.1 × 10–8). We also identified 29 additional vari-
ants with P < 5 × 10–7 in secondary analyses, a level of 
significance suggestive of association.
Attempted replication of potential signals of 
association with response to recombinant GH
We first focused on the 2 signals that reached sug-
gestive significance in our primary analysis: rs7628585 
near B4GALT4 and rs1977748 near TBCE. Neither of 
these signals were replicated nor reached genome-wide 
significance (Table  2). We also attempted to replicate 
the 5 signals that had reached genome-wide significance 
in a secondary analysis, meta-analyzing the discovery 
and replication samples using either the same model for 
which we observed the best evidence for association in 
the discovery sample or using the primary analysis (min-
imal covariates, all diagnoses) to maximize power. Two 
signals for which we were able to obtain replication data 
retained genome-wide significance after meta-analysis 
(rs55704135 near UBE4B; meta-analysis P = 2.65 × 10–8 
in the European ancestry/all diagnoses/maximum 
covariate analysis, and rs78263566 near CLEC7A; 
meta-analysis P = 1.67 × 10–8 in the European ancestry/
GHD/maximum covariate analysis, Table 2). However, 
for both of these signals, the evidence for association de-
creased after replication, so further validation of these 
associations would be needed. Two other genome-wide 
significant variants, (rs189532746, between CPOX and 
ST3GAL6, and rs78263566, between CLEC7A and 
OLR1) were not polymorphic in the replication ana-
lysis, and we were unable to successfully genotype the 
fifth signal (rs144751704, located in NT5DC1 and up-
stream of COL10A1) in the replication sample.
We also attempted to replicate 29 signals with sug-
gestive signals in secondary analyses. Of the 19 signals 
that were successfully genotyped, 12 were polymorphic 
in the replication sample, and 2 achieved genome-
wide significance in meta-analysis with the replica-
tion data when analyzed under the same model as was 
Figure 2. Quantile-quantile (QQ) plot for results from the primary 
association analysis of common variants with growth hormone 
response. Each point represents the result from a single variant 
(genotyped or imputed), ranked by observed P value. The x-axis 
indicates the expected P value and the y-axis indicates the observed P 
value, both in negative log scales. The gray line is the expected result 
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highlighted by the discovery sample. These 2 signals were 
rs75922185 near MGAT5; meta-analysis P = 4.93 × 10–8  
in the European ancestry/all diagnoses/maximum 
covariate analysis, and rs151058087 near AEBP2; 
meta-analysis P = 1.67 × 10–8 in the all ancestry/ISS/
maximum covariate analysis (Online Supplementary 
Table 1) (36). The variant near AEBP2 was the only 
one to achieve nominal significance in the replica-
tion sample. Of potential interest, rs115307564 near 
RBMS3, strongly replicated under the primary ana-
lysis model (replication P = 7.96 × 10–4, meta-analysis 
P = 1.67 × 10–6; Online Supplementary Table 1) (36). 
This variant therefore represents another promising 
signal of association.
Association analysis of rarer coding variation with 
response to recombinant GH using exome array 
genotypes
To determine the role of low-frequency coding vari-
ants, we also analyzed directly genotyped coding SNPs 
present on the exome array platforms. In single-variant 
analysis, no SNPs were significant after correcting for 
multiple testing (see Methods). Because single-variant 
tests are often underpowered to detect associations with 
rare variants, we also carried out gene-based associ-
ation tests using missense, splice, and loss-of-function 
variants within each gene (see Methods), combining in-
formation from the different variants in each gene using 
the sequence kernel association test (32), and limiting 
analysis to variants below 1%. No genes were signifi-
cant after correcting for multiple testing (see Methods). 
A full set of association results for our primary analysis 
for all variants with MAF above 1% and all directly 
genotyped coding variants will be made available.
GWAS analysis of variants previously associated 
with GH response or adult height
We also focused specifically on candidate 
polymorphisms previously associated with response 
to GH, including the GHR d3 variant (10-12), which 
is represented in our study by the highly correlated 
SNP rs6873545 (37), as well as the rs2854744 poly-
morphism in the IGFBP-3 promoter (13, 38). We con-
firmed that the rs6873545 was a good proxy for the 
GHR d3 variant in our study (see Methods). We ob-
served no evidence at either of these variants for associ-
ation with response to GH (P > 0.05 under all models). 
Thus, we could not replicate the previous associations.
We also tested a hypothesis that genetic predispos-
ition to tall or short stature could influence response 
to GH. For each individual, we constructed a genetic 
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Position on chr3 (Mb)
Plotted SNPs
Figure 3. LocusZoom plot for the B4GALT4 locus. The x-axis indicates position on chromosome 3 surrounding the lead signal of association near 
B4GALT4, rs7628585. Genes depicted in their respective locations. Each dot is a variant in the region tested and is colored by its correlation (r2) 
with rs7628585 according to the color key. Blue lines indicate recombination rates. The arrow and circle indicate the location and association signal 
of the second signal at B4GALT4, rs35583194; this insertion/deletion variant was not included in the LocusZoom plot because it is not present in 
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height variants and tested for association between this 
polygene score and the response to GH. We did not see 
even nominally significant evidence of association, sug-
gesting that genetic control of final height and response 
to GH are not strongly connected.
Discussion
We report what is, to our knowledge, the largest GWAS 
of response to GH to date. We leveraged the large 
sample size to interrogate both a primary analysis (all 
samples, with a minimal set of covariates) as well as 
several secondary analyses, including testing for associ-
ation in all samples and in European samples only, with 
specific diagnoses (ISS and GHD), and adjusting for a 
larger set of known clinical covariates (gestational age, 
age at start of GH therapy, GH dosage, height SDS at 
start of GH therapy, MPH).
We detected 37 suggestive associations (P < 5 × 10–7) 
from this GWAS, including 3 suggestive associations 
from our primary analysis and 5 that had P values 
below 5 × 10–8 in at least 1 secondary analysis. The 
strongest of the associations in the primary analysis was 
with common variation near the B4GALT4 and TBCE 
genes. However, despite these strongly suggestive genetic 
data, we did not observe associations with GH response 
in our replication sample. Possible explanations for the 
lack of replication include lack of power in the replica-
tion sample, differences in ethnicity (and hence different 
levels of linkage disequilibrium with an untyped causal 
variant), or that both of these suggestive associations 
are statistical fluctuations rather than true associations. 
Interestingly, the B4GALTT4 gene is 1 of 7 beta-1,4-
galactosyltransferase (beta4GalT) genes, and mutations 
in B4GALT7 lead to abnormal skeletal growth (39). 
However, mutations in B4GALT4 have not yet been 
reported to be associated with any specific disease. Of 
interest, a low-frequency variant that reached genome-
wide significance in a secondary analysis is located near 
ST3GAL6, a sialyltransferase that acts in the same 
pathway as the beta4GalT genes. The frequency of this 
variant was too low to robustly perform replication.
Of the remaining variants that we were able to assay 
in the replication sample (see Methods), 4 signals had 
meta-analysis P values that reached or retained genome-
wide significance in secondary analysis (near UBE4B, 
CLEC7A, MGAT5, and AEBP2). Remarkably, MGAT5 
also encodes a glycosyltransferase, although not ob-
viously in the same pathway as the beta4GalT genes. 
Thus, our results provide an intriguing suggestion that 
variation in glycosylation pathways may regulate the re-
sponse to GH.
Another low-frequency variant, near RBMS3, was 
the only one to show a strong signal in the replication 
cohort primary analysis but did not reach genome-
wide significance. RBMS3 encodes a long noncoding 
ribonucleic acid that may modulate signaling by trans-
forming growth factor beta, a well-known modulator 
of growth; of note, the TGFBR2 gene is adjacent to 
RBMS3. This variant, as well as the variants described 
in the previous paragraphs, represents signals that 
would benefit from further validation to see if they are 
robustly associated with GH response.
We also tested variants previously associated with re-
sponse to recombinant GH (rhGH), including the exon 
3 deletion variant in GHR (10-12) and the rs2854744 
and rs924140 variants in IGFBP3 (13, 38). We found 
no evidence of association with response to rhGH for 
any of these variants (all P > 0.05). One possibility why 
we failed to see an association in our large sample is that 
the findings from the prior studies are false-positives. We 
note that our study population is a heterogeneous col-
lection of patients with short stature, so differences in 
patient population could also explain these discrepant 
findings. However, we also saw no evidence of associ-
ation when we restricted our analysis to patients with 
ISS or to those with GHD.
We also tested whether the 697 height-associated 
loci are associated with response to rhGH. We found 
no strong association with GH response for any height-
associated loci, either individually or jointly. One pos-
sible explanation is that the GH response is regulated 
by different biological mechanisms than for height; 
another possible explanation is that variation in GH 
response is associated with variants that are rare and 
have not been identified from previous GWAS analyses. 
Comprehensive sequencing of samples with data on GH 
response could help address these possibilities. For ex-
ample, if a fraction of patients treated with GH have 
rare, nearly mendelian causes of short stature, then the 
variable response to GH could be partly dictated by the 
variable underlying etiologies in these patients.
Limitations of our study include the collection of 
samples from various locations in the world with 
various ethnic backgrounds, and a mixture of diag-
noses. We addressed this heterogeneity by performing 
secondary analyses of more homogeneous, if smaller, 
subgroups of individuals. The sample size is larger 
than previous studies but still quite small as compared 
with many GWAS studies and, therefore, has limited 
power to detect variants associated with GH response. 
A sample size of 614 should have 80% power to detect 
associations that explain, in our heterogeneous popu-
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effect sizes this large are unusual for polygenic traits, 
large effect sizes have been seen in other pharmacogen-
omics scenarios. Thus, any heritable contribution to 
GH response is likely polygenic. While our work shows 
that there are likely no common variants that on their 
own have clinically significant predictive power, larger 
sample sizes would be needed to identify variants with 
smaller effects that in combination, as part of a poly-
genic risk score, could still provide meaningful predic-
tion of the response to GH.
Our study only examined the relationship between 
genotype and growth response. As noted earlier, other 
approaches, such as gene expression profiling, can look 
at other molecular predictors of GH response, and these 
alternate approaches have been reviewed elsewhere (40). 
For example, 1 study looked at the methylation status of 
the IGF-1 promoter and found that approximately 25% 
of the first-year GH response may be attributable to 
differences in methylation at the P2 promoter of IGF-1 
(41). Additionally, while our study focused on first-year 
height response, consideration must be given to other 
definitions of GH responsiveness including biochemical, 
transcriptomic, and proteomic responses, which may 
offer more mechanistic insights into GH biology.
In summary, we have completed the largest genetic 
study to date of response to GH. We were unable to 
replicate previous associations, nor do we identify any 
new variants that are clearly and robustly associated 
with GH response. However, some associations reached 
genome-wide significance in secondary analyses and 
merit further investigation, and our data collectively 
raise the hypothesis that variation in glycosylation may 
contribute to variation in GH response. Larger sample 
sizes will be needed to more definitively identify any gen-
etic factors that robustly influence the response to GH.
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